Home > In process > Longitudinal monitoring of tau aggregation in progressive supranuclear palsy with [18F]PI-2620 PET. > print

001     285478
005     20260309095117.0
024 7 _ |a 10.1002/alz.71195
|2 doi
024 7 _ |a pmid:41736364
|2 pmid
024 7 _ |a pmc:PMC12932912
|2 pmc
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
037 _ _ |a DZNE-2026-00255
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Gnörich, Johannes
|0 P:(DE-2719)9001652
|b 0
|e First author
|u dzne
245 _ _ |a Longitudinal monitoring of tau aggregation in progressive supranuclear palsy with [18F]PI-2620 PET.
260 _ _ |a Hoboken, NJ
|c 2026
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1773046068_14565
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Progressive supranuclear palsy (PSP), a 4-repeat tauopathy, can be visualized using [18F]PI-2620 tau positron emission tomography (PET). However, the value of sequential [18F]PI-2620 imaging for tracking tau accumulation during the disease course has not yet been investigated.Twenty-three PSP patients underwent two [18F]PI-2620 PET scans (interval: 21.4 ± 4.3 months) and were compared to cross-sectional data from 25 healthy controls. Regional volume of distribution ratio values were analyzed for longitudinal tau changes, clinical correlations, and network-based propagation. Post mortem analyses examined neuronal density and AT8 tau pathology.Subcortical tau PET signals increased, strongest in the globus pallidus internus (P < 0.0001). Patients with low baseline tau showed the largest increases. Despite clinical worsening (Progressive Supranuclear Palsy Rating Scale +48%), tau PET change did not correlate with symptom progression. Tau accumulation followed functional connectivity (R = 0.34, P < 0.0001). Post mortem data linked elevated tau PET to higher AT8 burden despite neuronal loss.[18F]PI-2620 PET enables monitoring of tau progression in PSP, indicating network-based tau propagation with saturation in advanced stages.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 1
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 2
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a 4‐repeat tauopathies
|2 Other
650 _ 7 |a disease monitoring
|2 Other
650 _ 7 |a progressive supranuclear palsy
|2 Other
650 _ 7 |a tau positron emission tomography
|2 Other
650 _ 7 |a tau spreading
|2 Other
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a Fluorine Radioisotopes
|2 NLM Chemicals
650 _ 7 |a PI-2620
|2 NLM Chemicals
650 _ 7 |a Pyridines
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: diagnostic imaging
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: metabolism
|2 MeSH
650 _ 2 |a Supranuclear Palsy, Progressive: pathology
|2 MeSH
650 _ 2 |a Positron-Emission Tomography
|2 MeSH
650 _ 2 |a tau Proteins: metabolism
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Brain: metabolism
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Cross-Sectional Studies
|2 MeSH
650 _ 2 |a Fluorine Radioisotopes
|2 MeSH
650 _ 2 |a Pyridines
|2 MeSH
700 1 _ |a Kusche-Palenga, Julia
|b 1
700 1 _ |a Palleis, Carla
|0 P:(DE-2719)9000852
|b 2
|u dzne
700 1 _ |a Neubauer, Antonia
|0 P:(DE-2719)9002868
|b 3
|u dzne
700 1 _ |a Frontzkowski, Lukas
|b 4
700 1 _ |a Jäck, Alexander
|0 P:(DE-2719)9002626
|b 5
|u dzne
700 1 _ |a Kling, Agnes
|b 6
700 1 _ |a Bauer, Theresa
|b 7
700 1 _ |a Eyob, Hannah
|b 8
700 1 _ |a Probst, Katharina
|b 9
700 1 _ |a Roemer-Cassiano, Sebastian N
|b 10
700 1 _ |a Bernhardt, Alexander M
|0 P:(DE-2719)9002620
|b 11
|u dzne
700 1 _ |a Katzdobler, Sabrina
|0 P:(DE-2719)9001160
|b 12
|u dzne
700 1 _ |a Marth, Lena
|0 P:(DE-2719)9003208
|b 13
|u dzne
700 1 _ |a Zaganjori, Mirlind
|b 14
700 1 _ |a Hopfner, Franziska
|0 P:(DE-2719)9003372
|b 15
|u dzne
700 1 _ |a Zwergal, Andreas
|b 16
700 1 _ |a Häckert, Jan
|b 17
700 1 _ |a Rullmann, Michael
|b 18
700 1 _ |a Sabri, Osama
|0 P:(DE-2719)2814810
|b 19
|u dzne
700 1 _ |a Barthel, Henryk
|b 20
700 1 _ |a Stöcklein, Sophia
|0 P:(DE-2719)9003671
|b 21
|u dzne
700 1 _ |a Werner, Rudolf A
|b 22
700 1 _ |a Simons, Mikael
|0 P:(DE-2719)2811642
|b 23
|u dzne
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 24
|u dzne
700 1 _ |a Herms, Jochen
|0 P:(DE-2719)2810441
|b 25
|u dzne
700 1 _ |a Franzmeier, Nicolai
|b 26
700 1 _ |a Höglinger, Günter U
|0 P:(DE-2719)2811373
|b 27
|u dzne
700 1 _ |a Brendel, Matthias
|0 P:(DE-2719)9001539
|b 28
|e Last author
|u dzne
700 1 _ |a Tauopathies, German Imaging Initiative for
|b 29
|e Collaboration Author
773 _ _ |a 10.1002/alz.71195
|g Vol. 22, no. 2, p. e71195
|0 PERI:(DE-600)2201940-6
|n 2
|p e71195
|t Alzheimer's and dementia
|v 22
|y 2026
|x 1552-5260
856 4 _ |u https://pub.dzne.de/record/285478/files/DZNE-2026-00255.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/285478/files/DZNE-2026-00255.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)9001652
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000852
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9002868
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)9002626
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 11
|6 P:(DE-2719)9002620
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)9001160
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)9003208
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 15
|6 P:(DE-2719)9003372
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 19
|6 P:(DE-2719)2814810
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 21
|6 P:(DE-2719)9003671
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 23
|6 P:(DE-2719)2811642
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2811659
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)2810441
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2811373
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 28
|6 P:(DE-2719)9001539
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 2
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-11-11
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-11-11
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-11-11
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-11-11
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-11-11
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-11-11
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass
|l Molecular Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 1
920 1 _ |0 I:(DE-2719)1110001
|k AG Herms
|l Translational Brain Research
|x 2
920 1 _ |0 I:(DE-2719)1110008
|k AG Simons
|l Molecular Neurobiology
|x 3
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 4
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)1110007
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)1110001
980 _ _ |a I:(DE-2719)1110008
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21